IMRX — Immuneering Corp
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2021-07-30.
Performance
Technicals
Others in Healthcare
Measured signals that fired on IMRX
| date | signal | measured base rate |
|---|---|---|
| 2026-06-03 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
| 2026-05-22 | Equal highs taken out structure | -0.70% over 21 days · t = -8.28 · n = 68,636 statistically distinguishable from its control group |
| 2026-04-13 | Equal highs taken out structure | -0.70% over 21 days · t = -8.28 · n = 68,636 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-06-23 | Zeskind Benjamin J. PRESIDENT AND CEO | Open-market purchase | 2.4K | 4.56 | 10.9K |
| 2026-06-15 | Hall Brett Matthew CHIEF SCIENTIFIC OFFICER | Open-market purchase | 6.0K | 4.15 | 25.0K |
| 2026-03-13 | Neufeld Leah R CHIEF PEOPLE OFFICER | Grant or award | 3.6K | 4.29 | 15.6K |
| 2026-01-16 | Brakewood Harold Eugene Chief Business Officer | Open-market purchase | 5.2K | 4.76 | 25.0K |
| 2026-01-15 | Schall Thomas J. Director | Open-market purchase | 21.6K | 4.67 | 101.1K |
| 2026-01-15 | Hall Brett Matthew CHIEF SCIENTIFIC OFFICER | Open-market purchase | 2.3K | 4.57 | 10.5K |
| 2026-01-13 | Neufeld Leah R CHIEF PEOPLE OFFICER | Open-market purchase | 2.6K | 4.15 | 10.9K |
| 2026-01-12 | Feinberg Peter Director | Open-market purchase | 20.0K | 4.35 | 87.0K |
| 2025-10-03 | Feinberg Peter Director | Open-market purchase | 7.5K | 6.67 | 50.0K |
| 2025-10-01 | Bookman Michael CHIEF LEGAL OFFICER, SECRETARY | Open-market purchase | 1.0K | 6.83 | 7.0K |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| FMR LLC | 51.1M | 9.7M |
| Sanofi | 14.3M | 2.7M |
| MARSHALL WACE, LLP | 10.5M | 2.0M |
| BlackRock, Inc. | 7.9M | 1.5M |
| MILLENNIUM MANAGEMENT LLC | 5.8M | 1.1M |
| GEODE CAPITAL MANAGEMENT, LLC | 3.4M | 637.9K |
| Occam Crest Management LP | 2.9M | 545.1K |
| CITADEL ADVISORS LLC | 2.4M | 447.3K |
| Connor, Clark & Lunn Investment Management Ltd. | 2.1M | 400.4K |
| Summit Financial, LLC | 2.0M | 376.7K |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Ask the AI about IMRX
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →